BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), (NASDAQ:CYCCP) and independent investigators presented eight posters at the annual meeting of the American Association for Cancer Research (AACR) with preclinical data demonstrating the ability of Cyclacel’s cell cycle inhibitors to induce cancer cell death, or apoptosis, by inhibiting key enzymes. Five of these preclinical studies evaluated Cyclacel’s CYC116 cell cycle inhibitor. The studies provide additional evidence that CYC116 inhibits Aurora kinases and Vascular Endothelial Growth Factor Receptor-2 tyrosine kinase or VEGFR-2 kinase. Aurora kinases are target proteins that are essential for mitosis or the process by which a cell divides. VEGFR-2 kinase is a validated target promoting angiogenesis or new vessel formation in the vicinity of cancer cells
